Comparative safety and efficacy of urokinase and recombinant tissue plasminogen activator for peripheral arterial occlusion: A meta-analysis

Pharmacotherapy

Volumn 26, Issue 1, 2006, Pages 51-60

  Sander, Stephen ^a,b   White, C Michael ^a,b   Coleman, Craig I ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Peripheral arterial occlusion; Recombinant tissue plasminogen activator; Urokinase

Indexed keywords

ALTEPLASE; UROKINASE;

BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; HUMAN; META ANALYSIS; MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNITED STATES;

EID: 30544452135     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2006.26.1.51     Document Type: Review

References (32)

1. Criqui MH. Peripheral arterial disease-epidemiological aspects. Vasc Med 2001;6:3-7.
2. Matsumoto AH, Cannon BC, Silva MB. Update: the use of fibrinolytic therapy in the management of peripheral arterial occlusion and deep vein thrombosis. Clinical and cost considerations. Clinician 2004;21:3-15.
3. The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. Ann Surg 1994;220:251-68.
4. Cina CS, Goh RH, Chan J, et al. Intraarterial catheter-directed thrombolysis: urokinase versus tissue plasminogen activator. Ann Vasc Surg 1999;13:571-5.
5. Graor RA, Olin JW, Bacharach M. Comparison of tPA and urokinase for peripheral arterial thrombolysis. J Vasc Med Biol 1993;4:311-14.
6. Mahler F, Schneider E, Hess H. Recombinant tissue plasminogen activator versus urokinase for local thrombolysis of femoropopliteal occlusions: a prospective, randomized multicenter trial. J Endovasc Ther 2001;8:638-47.
7. Meyerovitz MF, Goldhaber SZ, Reagan K, et al. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial. Radiology 1990;175:75-8.
8. Schweizer J, Altman E, Stoblein F, Florek H, Kaulen R. Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions. Eur J Radiol 1996;22:129-32.
9. Ouriel K, Kaul AF, Leonard MC. Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis. J Vasc Surg 2004;40:971-7.
10. Ouriel K, Gray B, Clair DG, Olin J. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis. J Vasc Interv Radiol 2000;11:295-8.
11. Shortell CK, Queiroz R, Johansson M, et al. Safety and efficacy of limited-dose tissue plasminogen activator in acute vascular occlusion 2001;34:854-9.
12. Sugimoto K, Hofmann LV, Razavi MK, et al. The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions. J Vasc Surg 2003;37:512-17.
13. Dickersin K, Scherer R, Lefebvre C. Systematic review, identifying relevant studies for systematic reviews. BMJ 1994;309:1286-91.
14. Comerota AT. Thrombolytic therapy in peripheral arterial occlusive disease: mechanisms of action and drugs available. Can J Surg 1993;36:342-8.
15. The ASSENT-2 Investigators. Single-bolus compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999;354:716-22.
16. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with myocardial infarction: the RAPID II investigators. Circulation 1996;94:891-8.
17. Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment: gruppo Italiano per lo studio della sopravvivenza nell'infarto miocardico II (GISSI-2), and the international study group. N Engl J Med 1992;327:1-6.
18. The GUSTO. Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
19. Anonymous. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (third international study of infarct survival) collaborative group. Lancet 1992;339(8796):753-70.
20. Weitz JI. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding. J Vasc Intervent Radiol 1995;6(suppl 2):19S-23.
21. Bell WR. Therapeutic agents: pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med 2002;3(suppl 2):S34-44.
22. Cannon CP, Gibson M, McCabe CG, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation 1998;98:2805-14.
23. Ouriel K. Thrombolytic solutions for peripheral vascular disease: summary and conclusions. Rev Cardiovasc Med 2002;3:S100-3.
24. Califf RM, Topol EJ, George BS, et al. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. Am J Med 1988;875:353-9.
25. Ouriel K, Welch EL, Shortell CK, Fiore WM, Cimino C. Comparison of streptokinase, urokinase, and recombinant tissue plasminogen activator in an in vitro model of venous thrombolysis. J Vasc Surg 1995;22(5):593-7.
26. Deitcher SR, Jaff MR. Pharmacologic and clinical characteristics of thrombolytic agents. Rev Cardiovasc Med 2002;3:S25-33.
27. Ward AS, Andaz SK, Bygrave S. Peripheral thrombolysis with tissue plasminogen activator. Results of two treatment regimens. Arch Surg 1994;129(8):861-5.
28. Braithwaite BD, Buckenham TM, Galland RB, Heather BP, Earnshaw JJ. Prospective randomized trial of high-dose versus low-dose tissue plasminogen activator infusion in the management of acute limb ischaemia. Br J Surg 1997;84:646-60.
29. Ouriel K, Kandarpa K. Safety of thrombolytic therapy with urokinase or recombinant tissue plasminogen activator for peripheral arterial occlusion: a comprehensive compilation of published work. J Endovasc Ther 2004;11:436-46.
30. Anonymous. Thrombolysis in the management of lower limb peripheral arterial occlusion: a consensus document. Working party on thrombolysis in the management of limb ischemia. Am J Cardiol 1998;81:207-18.
31. Semba CP, Bakal CW, Calis KA, et al. Alteplase as an alternative to urokinase. J Vasc Interv Radiol 2000;11:279-87.
32. Ouriel K, Veith FJ, Sasahara AA. Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators. J Vasc Surg 1996;23:64-73.